PhRMA’s Defensive Move On DTC Ads: Putting Drug List Prices ‘In Context’
Executive Summary
Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.
You may also be interested in...
TV Drug Advertising Spend Rising, But Few Brands Provide Pricing Info
DTC spending had shown an uptick in 2020 compared with 2019. Many advertisers are not, however, providing clear drug pricing information in their TV spots, despite some voluntary commitments to do so.
Gottlieb Tells Brand Firms To Sell Samples For Generics – Or Face The Consequences
The idea could help quiet growing criticism over system gaming and high drug prices.
After DTC Rule Tossed Out In Court, Attention Turns (Again) To Congress
HHS lacks authority to require drug price disclosures in TV ads, judge rules. Even if legislation were to explicitly give the Trump Administration such authority, First Amendment issues would still linger.